Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Crispr Therapeutics Ag (CRSP) since 2016 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Crispr Therapeutics Ag. (See page 1 of this report.) Table 2 shows the detailed insider transactions. This company's CIK number is 1674416.
Total stock buying since 2016: $293,942,208.
Total stock sales since 2016: $373,417,799.
Total stock option exercises since 2016: $19,239,965.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 4,976,060 | $258,954,140 | 124,854 | $6,280,789 | 157,497 | $0 |
| 2024 | 0 | $0 | 213,469 | $13,804,447 | 210,103 | $2,477,607 |
| 2023 | 0 | $0 | 125,000 | $6,506,300 | 178,754 | $2,390,000 |
| 2022 | 0 | $0 | 150,000 | $9,148,625 | 292,152 | $2,545,901 |
| 2021 | 0 | $0 | 398,877 | $62,188,865 | 382,267 | $2,802,515 |
| 2020 | 0 | $0 | 963,688 | $100,088,841 | 493,985 | $6,475,496 |
| 2019 | 0 | $0 | 459,118 | $21,805,542 | 141,618 | $778,761 |
| 2018 | 724,346 | $16,626,368 | 2,353,910 | $113,098,938 | 185,500 | $1,065,394 |
| 2017 | 0 | $0 | 2,185,156 | $40,495,452 | 285,421 | $704,291 |
| 2016 | 1,311,550 | $18,361,700 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2020-12-09 | Kasinger James R. (General Counsel and Secretary) | Option Ex | 22,026 | 13.62 | 299,994 |
| 2020-12-07 | Bolzon Bradley J Phd (Director) | Sale | 171,004 | 154.02 | 26,337,352 |
| 2020-11-30 | Novak Rodger (President) | Sale | 100,000 | 125.00 | 12,500,000 |
| 2020-11-30 | Novak Rodger (President) | Option Ex | 100,000 | 14.21 | 1,421,500 |
| 2020-10-09 | Novak Rodger (President) | Sale | 2,762 | 100.00 | 276,200 |
| 2020-10-09 | Novak Rodger (President) | Option Ex | 2,762 | 14.43 | 39,855 |
| 2020-10-08 | Novak Rodger (President) | Sale | 22,238 | 100.00 | 2,223,800 |
| 2020-10-08 | Novak Rodger (President) | Option Ex | 22,238 | 14.43 | 320,894 |
| 2020-09-18 | Bolzon Bradley J Phd (Director) | Sale | 3,035 | 86.86 | 263,635 |
| 2020-09-16 | Bolzon Bradley J Phd (Director) | Sale | 8,965 | 86.98 | 779,775 |
| 2020-09-14 | Bolzon Bradley J Phd (Director) | Sale | 1,155 | 84.89 | 98,045 |
| 2020-09-10 | Bolzon Bradley J Phd (Director) | Sale | 22,845 | 85.46 | 1,952,379 |
| 2020-09-01 | Novak Rodger (President) | Sale | 25,000 | 92.44 | 2,311,000 |
| 2020-09-01 | Novak Rodger (President) | Option Ex | 25,000 | 14.21 | 355,375 |
| 2020-09-01 | Tomsicek Michael John (Chief Financial Officer) | Sale | 12,000 | 92.27 | 1,107,204 |
| 2020-09-01 | Tomsicek Michael John (Chief Financial Officer) | Option Ex | 12,000 | 17.75 | 213,000 |
| 2020-09-01 | Bolzon Bradley J Phd (Director) | Sale | 60,000 | 92.60 | 5,556,000 |
| 2020-09-01 | Bolzon Bradley J Phd (Director) | Option Ex | 60,000 | 28.98 | 1,738,620 |
| 2020-08-19 | Novak Rodger (President) | Sale | 25,000 | 100.00 | 2,500,000 |
| 2020-08-19 | Novak Rodger (President) | Option Ex | 25,000 | 14.00 | 350,000 |
| 2020-08-03 | Tomsicek Michael John (Chief Financial Officer) | Sale | 12,000 | 86.79 | 1,041,516 |
| 2020-08-03 | Tomsicek Michael John (Chief Financial Officer) | Option Ex | 12,000 | 17.75 | 213,000 |
| 2020-07-07 | Novak Rodger (President) | Sale | 25,000 | 90.00 | 2,250,000 |
| 2020-07-07 | Novak Rodger (President) | Option Ex | 25,000 | 7.91 | 197,625 |
| 2020-07-06 | Bolzon Bradley J Phd (Director) | Sale | 20,000 | 82.58 | 1,651,639 |
| 2020-07-01 | Novak Rodger (President) | Sale | 50,000 | 80.00 | 4,000,000 |
| 2020-06-25 | Klein Lawrence Otto (CBO & COO) | Sale | 4,912 | 75.18 | 369,274 |
| 2020-06-25 | Klein Lawrence Otto (CBO & COO) | Option Ex | 4,912 | 12.57 | 61,743 |
| 2020-06-24 | Klein Lawrence Otto (CBO & COO) | Sale | 65,088 | 75.91 | 4,940,569 |
| 2020-06-24 | Klein Lawrence Otto (CBO & COO) | Option Ex | 65,088 | 9.21 | 599,785 |
| 2020-06-23 | Ho Tony W (Executive VP, Head of R&D) | Sale | 6,929 | 75.20 | 521,060 |
| 2020-06-23 | Novak Rodger (President) | Sale | 50,000 | 75.00 | 3,750,000 |
| 2020-06-23 | Bolzon Bradley J Phd (Director) | Sale | 10,000 | 75.34 | 753,450 |
| 2020-06-22 | Ho Tony W (Executive VP, Head of R&D) | Sale | 229 | 70.14 | 16,062 |
| 2020-06-22 | Bolzon Bradley J Phd (Director) | Sale | 10,000 | 72.51 | 725,070 |
| 2020-06-01 | Kulkarni Samarth (Chief Executive Officer) | Sale | 17,275 | 64.48 | 1,113,892 |
| 2020-06-01 | Kulkarni Samarth (Chief Executive Officer) | Option Ex | 17,275 | 1.81 | 31,267 |
| 2020-05-26 | Ho Tony W (Executive VP, Head of R&D) | Sale | 6,100 | 70.14 | 427,854 |
| 2020-05-26 | Novak Rodger (President) | Sale | 36,616 | 70.27 | 2,573,006 |
| 2020-05-22 | Ho Tony W (Executive VP, Head of R&D) | Sale | 600 | 70.05 | 42,030 |
| 2020-05-22 | Novak Rodger (President) | Sale | 13,384 | 70.01 | 937,013 |
| 2020-05-20 | Kulkarni Samarth (Chief Executive Officer) | Sale | 10,693 | 65.28 | 698,039 |
| 2020-05-20 | Kulkarni Samarth (Chief Executive Officer) | Option Ex | 10,693 | 1.81 | 19,354 |
| 2020-05-19 | Kulkarni Samarth (Chief Executive Officer) | Sale | 4,307 | 65.16 | 280,644 |
| 2020-05-19 | Kulkarni Samarth (Chief Executive Officer) | Option Ex | 4,307 | 1.81 | 7,795 |
| 2020-05-19 | Novak Rodger (President) | Sale | 50,000 | 65.00 | 3,250,000 |
| 2020-05-11 | Klein Lawrence Otto (CBO & COO) | Sale | 25,000 | 60.73 | 1,518,125 |
| 2020-05-11 | Klein Lawrence Otto (CBO & COO) | Option Ex | 25,000 | 5.86 | 146,500 |
| 2020-03-05 | Ho Tony W (Executive VP, Head of R&D) | Option Ex | 3,333 | .00 | 0 |
| 2019-12-16 | Kulkarni Samarth (Chief Executive Officer) | Option Ex | 8,000 | 1.81 | 14,480 |
| 2019-11-19 | Novak Rodger (President) | Sale | 33,618 | 70.00 | 2,353,260 |
| 2019-11-19 | Novak Rodger (President) | Option Ex | 33,618 | 14.43 | 485,107 |
| 2019-11-19 | Bolzon Bradley J Phd (Director) | Sale | 42,000 | 67.41 | 2,831,388 |
| 2019-11-19 | Cagnoni Pablo J (Director) | Sale | 7,500 | 62.00 | 465,000 |
| 2019-11-19 | Cagnoni Pablo J (Director) | Option Ex | 7,500 | 5.59 | 41,925 |
| 2019-11-12 | Cagnoni Pablo J (Director) | Sale | 7,500 | 55.00 | 412,500 |
| 2019-11-12 | Cagnoni Pablo J (Director) | Option Ex | 7,500 | 5.59 | 41,925 |
| 2019-10-30 | Bolzon Bradley J Phd (Director) | Sale | 21,000 | 51.89 | 1,089,669 |
| 2019-10-30 | Cagnoni Pablo J (Director) | Sale | 7,500 | 52.00 | 390,000 |
| 2019-10-30 | Cagnoni Pablo J (Director) | Option Ex | 7,500 | 5.59 | 41,925 |
| 2019-08-01 | Ho Tony W (Executive VP, Head of R&D) | Option Ex | 37,500 | .00 | 0 |
| 2019-07-11 | Klein Lawrence Otto (Chief Business Officer) | Sale | 8,421 | 50.01 | 421,167 |
| 2019-07-11 | Klein Lawrence Otto (Chief Business Officer) | Option Ex | 8,421 | 5.86 | 49,347 |
| 2019-07-10 | Klein Lawrence Otto (Chief Business Officer) | Sale | 11,579 | 50.02 | 579,181 |
| 2019-07-10 | Klein Lawrence Otto (Chief Business Officer) | Option Ex | 11,579 | 5.86 | 67,852 |
| 2019-07-10 | Novak Rodger (President) | Sale | 50,000 | 50.00 | 2,500,050 |
| 2019-06-17 | Kulkarni Samarth (Chief Executive Officer) | Sale | 20,000 | 46.00 | 920,000 |
| 2019-06-17 | Kulkarni Samarth (Chief Executive Officer) | Option Ex | 20,000 | 1.81 | 36,200 |
| 2019-06-10 | Novak Rodger (President) | Sale | 50,000 | 45.00 | 2,250,000 |
| 2019-03-04 | Novak Rodger (President) | Sale | 76,527 | 41.19 | 3,151,917 |
| 2019-03-01 | Novak Rodger (President) | Sale | 8,693 | 40.01 | 347,798 |
| 2019-02-25 | Novak Rodger (President) | Sale | 14,780 | 40.00 | 591,229 |
| 2019-01-09 | Novak Rodger (President) | Sale | 82,690 | 35.01 | 2,894,976 |
| 2019-01-08 | Novak Rodger (President) | Sale | 17,310 | 35.09 | 607,407 |
| 2018-12-27 | Vertex Pharmaceuticals Inc / Ma (10% Owner) | Buy | 27,461 | 24.95 | 685,124 |
| 2018-12-26 | Vertex Pharmaceuticals Inc / Ma (10% Owner) | Buy | 12,737 | 24.89 | 317,074 |
| 2018-12-24 | Vertex Pharmaceuticals Inc / Ma (10% Owner) | Buy | 68,000 | 23.69 | 1,610,716 |
| 2018-12-21 | Vertex Pharmaceuticals Inc / Ma (10% Owner) | Buy | 22,742 | 22.58 | 513,468 |
| 2018-12-18 | Emster Kurt Von | Sale | 69,925 | 29.70 | 2,077,122 |
| 2018-12-17 | Emster Kurt Von | Sale | 3,009 | 33.17 | 99,796 |
| 2018-12-07 | Kulkarni Samarth (Chief Executive Officer) | Option Ex | 21,500 | 1.81 | 38,915 |
| 2018-11-21 | Celgene Corp /de/ (10% Owner) | Sale | 80,000 | 19.25 | 1,540,000 |
| 2018-08-01 | Ho Tony W (See Remarks) | Option Ex | 37,500 | .00 | 0 |
| 2018-07-05 | Cagnoni Pablo J (Director) | Sale | 1,684 | 62.00 | 104,408 |
| 2018-07-05 | Cagnoni Pablo J (Director) | Option Ex | 1,684 | 5.59 | 9,413 |
| 2018-07-03 | Cagnoni Pablo J (Director) | Sale | 5,816 | 62.00 | 360,592 |
| 2018-07-03 | Cagnoni Pablo J (Director) | Option Ex | 5,816 | 5.59 | 32,511 |
| 2018-06-05 | Emster Kurt Von | Sale | 920 | 12.51 | 11,509 |
| 2018-06-01 | Kulkarni Samarth (Chief Executive Officer) | Sale | 15,000 | 68.78 | 1,031,700 |
| 2018-06-01 | Kulkarni Samarth (Chief Executive Officer) | Option Ex | 15,000 | 1.81 | 27,150 |
| 2018-05-17 | Novak Rodger (President) | Sale | 75,000 | 60.00 | 4,500,000 |
| 2018-05-17 | Novak Rodger (President) | Option Ex | 75,000 | 7.91 | 592,875 |
| 2018-05-15 | Woiwode Thomas (Director) | Sale | 44,000 | 58.35 | 2,567,400 |
| 2018-05-15 | Bolzon Bradley J Phd (Director) | Sale | 44,000 | 58.35 | 2,567,400 |
| 2018-05-14 | Emster Kurt Von | Sale | 400,000 | 54.43 | 21,773,200 |
| 2018-05-11 | Emster Kurt Von | Sale | 250,000 | 52.51 | 13,128,250 |
| 2018-05-08 | Woiwode Thomas (Director) | Sale | 1,653 | 51.45 | 85,046 |
| 2018-05-08 | Bolzon Bradley J Phd (Director) | Sale | 9,241 | 50.77 | 469,165 |
| 2018-05-07 | Woiwode Thomas (Director) | Sale | 119,709 | 50.78 | 6,079,421 |
| 2018-05-07 | Bolzon Bradley J Phd (Director) | Sale | 119,709 | 50.78 | 6,079,421 |
| 2018-04-30 | Woiwode Thomas (Director) | Sale | 30,566 | 50.28 | 1,536,950 |
| 2018-04-30 | Bolzon Bradley J Phd (Director) | Sale | 30,566 | 50.28 | 1,536,950 |
| 2018-04-27 | Woiwode Thomas (Director) | Sale | 11,648 | 50.03 | 582,807 |
| 2018-04-27 | Bolzon Bradley J Phd (Director) | Sale | 11,648 | 50.03 | 582,807 |
| 2018-04-26 | Woiwode Thomas (Director) | Sale | 210,610 | 50.12 | 10,554,720 |
| 2018-04-26 | Bolzon Bradley J Phd (Director) | Sale | 210,610 | 50.12 | 10,554,720 |
| 2018-04-24 | Woiwode Thomas (Director) | Sale | 22,841 | 50.90 | 1,162,606 |
| 2018-04-24 | Versant Venture Capital V (canada), Lp (10% Owner) | Sale | 22,841 | 50.90 | 1,162,606 |
| 2018-04-24 | Bolzon Bradley J Phd (Director) | Sale | 22,841 | 50.90 | 1,162,606 |
| 2018-04-23 | Woiwode Thomas (Director) | Sale | 101,994 | 50.83 | 5,184,355 |
| 2018-04-23 | Versant Venture Capital V (canada), Lp (10% Owner) | Sale | 101,994 | 50.83 | 5,184,355 |
| 2018-04-23 | Bolzon Bradley J Phd (Director) | Sale | 101,994 | 50.83 | 5,184,355 |
| 2018-01-16 | Dylan-hyde Tyler (Chief Legal Officer) | Sale | 66,000 | 28.11 | 1,855,458 |
| 2018-01-16 | Dylan-hyde Tyler (Chief Legal Officer) | Option Ex | 21,000 | 12.57 | 263,970 |
| 2018-01-05 | Bayer Global Investments B.v. (10% Owner) | Buy | 527,472 | 22.75 | 11,999,988 |
| 2018-01-05 | Emster Kurt Von | Buy | 65,934 | 22.75 | 1,499,998 |
| 2018-01-05 | Emster Kurt Von | Sale | 92,337 | 26.96 | 2,489,405 |
| 2018-01-02 | Dylan-hyde Tyler (Chief Legal Officer) | Sale | 38,000 | 23.15 | 879,700 |
| 2018-01-02 | Dylan-hyde Tyler (Chief Legal Officer) | Option Ex | 8,000 | 12.57 | 100,560 |
| 2018-01-02 | Emster Kurt Von | Sale | 37,754 | 26.75 | 1,010,108 |
| 2017-12-29 | Dylan-hyde Tyler (Chief Legal Officer) | Sale | 30,300 | 22.48 | 681,295 |
| 2017-12-29 | Dylan-hyde Tyler (Chief Legal Officer) | Option Ex | 15,300 | 13.50 | 206,550 |
| 2017-12-28 | Dylan-hyde Tyler (Chief Legal Officer) | Sale | 700 | 21.75 | 15,225 |
| 2017-12-28 | Dylan-hyde Tyler (Chief Legal Officer) | Option Ex | 700 | 14.43 | 10,101 |
| 2017-12-22 | Dylan-hyde Tyler (Chief Legal Officer) | Sale | 15,000 | 20.55 | 308,250 |
| 2017-12-22 | Woiwode Thomas (Director) | Sale | 3,059 | 20.29 | 62,070 |
| 2017-12-22 | Bolzon Bradley J Phd (Director) | Sale | 26,016 | 20.30 | 528,228 |
| 2017-12-21 | Kulkarni Samarth (Chief Executive Officer) | Option Ex | 15,000 | 1.81 | 27,150 |
| 2017-12-15 | Dylan-hyde Tyler (Chief Legal Officer) | Sale | 15,000 | 18.90 | 283,500 |
| 2017-12-04 | Celgene Corp /de/ (10% Owner) | Sale | 30,485 | 19.47 | 593,542 |
| 2017-12-01 | Celgene Corp /de/ (10% Owner) | Sale | 87,991 | 19.10 | 1,680,628 |
| 2017-11-30 | Celgene Corp /de/ (10% Owner) | Sale | 12,666 | 19.04 | 241,160 |
| 2017-11-29 | Celgene Corp /de/ (10% Owner) | Sale | 4,263 | 19.25 | 82,062 |
| 2017-11-28 | Celgene Corp /de/ (10% Owner) | Sale | 5,080 | 19.22 | 97,637 |
| 2017-11-27 | Woiwode Thomas (Director) | Sale | 200 | 20.24 | 4,047 |
| 2017-11-27 | Bolzon Bradley J Phd (Director) | Sale | 200 | 20.24 | 4,047 |
| 2017-11-27 | Celgene Corp /de/ (10% Owner) | Sale | 27,990 | 19.75 | 552,802 |
| 2017-11-24 | Woiwode Thomas (Director) | Sale | 1,700 | 20.21 | 34,358 |
| 2017-11-24 | Bolzon Bradley J Phd (Director) | Sale | 1,507 | 20.21 | 30,450 |
| 2017-11-24 | Celgene Corp /de/ (10% Owner) | Sale | 26,010 | 20.00 | 520,200 |
| 2017-11-22 | Celgene Corp /de/ (10% Owner) | Sale | 256,000 | 19.76 | 5,058,560 |
| 2017-11-20 | Celgene Corp /de/ (10% Owner) | Sale | 158,718 | 19.02 | 3,018,816 |
| 2017-11-17 | Celgene Corp /de/ (10% Owner) | Sale | 51,282 | 18.44 | 945,640 |
| 2017-11-16 | Celgene Corp /de/ (10% Owner) | Sale | 105,000 | 18.39 | 1,930,950 |
| 2017-11-15 | Celgene Corp /de/ (10% Owner) | Sale | 15,000 | 17.67 | 265,050 |
| 2017-11-14 | Celgene Corp /de/ (10% Owner) | Sale | 14,907 | 17.19 | 256,251 |
| 2017-11-13 | Celgene Corp /de/ (10% Owner) | Sale | 65,093 | 17.76 | 1,156,051 |
| 2017-11-10 | Celgene Corp /de/ (10% Owner) | Sale | 10,000 | 17.28 | 172,800 |
| 2017-11-09 | Celgene Corp /de/ (10% Owner) | Sale | 20,000 | 17.08 | 341,599 |
| 2017-11-08 | Celgene Corp /de/ (10% Owner) | Sale | 16,875 | 18.06 | 304,762 |
Insider trading activities including stock purchases, stock sales, and option exercises of CRSP listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Crispr Therapeutics Ag (symbol CRSP, CIK number 1674416) see the Securities and Exchange Commission (SEC) website.